{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "9804592", "DateCompleted": {"Year": "1998", "Month": "12", "Day": "29"}, "DateRevised": {"Year": "2017", "Month": "12", "Day": "13"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "8750-7587", "JournalIssue": {"Volume": "85", "Issue": "5", "PubDate": {"Year": "1998", "Month": "Nov"}}, "Title": "Journal of applied physiology (Bethesda, Md. : 1985)", "ISOAbbreviation": "J Appl Physiol (1985)"}, "ArticleTitle": "Nociceptive mechanisms modulate ozone-induced human lung function decrements.", "Pagination": {"StartPage": "1863", "EndPage": "1870", "MedlinePgn": "1863-70"}, "Abstract": {"AbstractText": ["We have previously suggested that ozone (O3)-induced pain-related symptoms and inhibition of maximal inspiration are due to stimulation of airway C fibers (M. J. Hazucha, D. V. Bates, and P. A. Bromberg. J. Appl. Physiol. 67: 1535-1541, 1989). If this were so, pain suppression or inhibition by opioid-receptor agonists should partially or fully reverse O3-induced symptomatic and lung functional responses. The objectives of this study were to determine whether O3-induced pain limits maximal inspiration and whether endogenous opioids contribute to modulation of the effects of inhaled O3 on lung function. The participants in this double-blind crossover study were healthy volunteers (18-59 yr) known to be \"weak\" (WR; n = 20) and \"strong\" O3 responders (SR; n = 42). They underwent either two 2-h exposures to air or two 2-h exposures to 0. 42 parts/million O3 with moderate intermittent exercise. Immediately after post-O3 spirometry, the WR were randomly given either naloxone (0.15 mg/kg iv) or saline, whereas SR randomly received either sufentanil (0.2 microgram/kg iv) or saline. O3 exposure significantly (P < 0.001) impaired lung function. In SR, sufentanil rapidly, although not completely, reversed both the chest pain and spirometric effects (forced expiratory volume in 1 s; P < 0.0001) compared with saline. Immediate postexposure administration of saline or naloxone had no significant effect on WR. Plasma beta-endorphin levels were not related to an individual's O3 responsiveness. Cutaneous pain variables showed a nonsignificant weak association with O3 responsiveness. These observations demonstrate that nociceptive mechanisms play a key role in modulating O3-induced inhibition of inspiration but not in causing lack of spirometric response to O3 exposure in WR."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anesthesiology, School of Medicine, University of North Carolina at Chapel Hill, USA."}], "Identifier": [], "LastName": "Passannante", "ForeName": "A N", "Initials": "AN"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hazucha", "ForeName": "M J", "Initials": "MJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Bromberg", "ForeName": "P A", "Initials": "PA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Seal", "ForeName": "E", "Initials": "E"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Folinsbee", "ForeName": "L", "Initials": "L"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Koch", "ForeName": "G", "Initials": "G"}], "PublicationTypeList": ["Clinical Trial", "Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't", "Research Support, U.S. Gov't, Non-P.H.S."]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Appl Physiol (1985)", "NlmUniqueID": "8502536", "ISSNLinking": "0161-7567"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Analgesics, Opioid"}, {"RegistryNumber": "0", "NameOfSubstance": "Narcotic Antagonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Oxidants, Photochemical"}, {"RegistryNumber": "36B82AMQ7N", "NameOfSubstance": "Naloxone"}, {"RegistryNumber": "60617-12-1", "NameOfSubstance": "beta-Endorphin"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "AFE2YW0IIZ", "NameOfSubstance": "Sufentanil"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Analgesics, Opioid"}, {"QualifierName": [], "DescriptorName": "Cross-Over Studies"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": ["physiology"], "DescriptorName": "Exercise"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects"], "DescriptorName": "Lung"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Naloxone"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Narcotic Antagonists"}, {"QualifierName": ["drug effects", "physiology"], "DescriptorName": "Nociceptors"}, {"QualifierName": ["toxicity"], "DescriptorName": "Oxidants, Photochemical"}, {"QualifierName": ["toxicity"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Respiratory Function Tests"}, {"QualifierName": [], "DescriptorName": "Spirometry"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Sufentanil"}, {"QualifierName": ["blood"], "DescriptorName": "beta-Endorphin"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1998", "Month": "11", "Day": "6"}, {"Year": "1998", "Month": "11", "Day": "6", "Hour": "0", "Minute": "1"}, {"Year": "1998", "Month": "11", "Day": "6", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["9804592", "10.1152/jappl.1998.85.5.1863"]}}], "PubmedBookArticle": []}